Late Discovery
antibody platform, S-DUAL™, the rapid developability assessment platform, DEVELOPICK™, and the transient expression platform,
S-CHOscient™.
Our expert team works closely with you to identify and mitigate scale-up challenges, addressing issues before they escalate into significant problems. We can accelerate your timelines with streamlined processes and workflows, empowering you to bring your innovations to market faster.
S-DUAL™
S-DUAL™ is an advanced bispecific antibody platform that generates perfect pairing every time. The dual-specificity of these antibodies opens up a wide range of applications, allowing you to reach commercialization more efficiently.
Our proprietary platform establishes an optimal path for development success.
- Asymmetric IgG-like structure
- Low immunogenicity risk
- Correct HC & LC pairing
- Streamlined access
Bispecific Antibody Platform Structure
-
- Low Immunogenicity Risk
-
- Similar structure to typical bispecific antibodies
- Antibody-derived protein only
-
- Correctly Paired bsAb
-
- Knob-into-Hole CH3 dimer applied on an additional domain in one Fab arm
- >95% purity
-
- Streamlined Access
-
- Favorable contract terms with competitive pricing
- Only parental antibody sequences needed to develop BsAb
A
B
Additional CH3 Domain
Knob-into-Hole
DEVELOPICK™
DEVELOPICK™ is a rapid and agile assessment tool that scores drug candidates based on developability criteria to provide early insights and selection guidance, maximizing time-and cost-efficiency.
Our proprietary platform establishes an optimal path for development success.
- Timely evaluation in just 1 month
- Efficient assessment with only 80 mg of material
- Systematic analysis for optimal decision making
Developability Assessment Workflow
DEVELOPICK™ predicts candidates with the best potential for advancement by suggesting optimal formulation and scoring drug candidates based on stability screening.
- Material Supply
- Primary Structure Assessment
- Relative Solubility
- Basic Characterization
- Heat Stress Treatment
- Low & High pH Treatment
- Hydrophobic Interaction Analysis
- Data Reporting
- Material Supply
- Primary Structure Assessment
- Relative Solubility
- Basic Characterization
- Heat Stress Treatment
- Low & High pH Treatment
- Hydrophobic Interaction Analysis
- Data Reporting
S-CHOsient™
S-CHOsient™ is a transient expression platform designed for the early generation of your molecule of interest.
With a reliable foundation for successful drug development, you can unleash the full potential of your molecules. S-CHOsient™ can:
- Generate material for internal study
- Test vector ratios for transfection
- Generate reference material for process development
Process Flow of S-CHOsient™
Experience higher productivity and quality with S-CHOsient™ designed for early generation of your molecule of interest.
- Gene Synthesis / Vector Construction
- Transfection / Main Culture and Harvest
- Purification / Analytics
- Gene Synthesis / Vector Construction
- Transfection / Main Culture and Harvest
- Purification / Analytics
Related Content
Asymmetrical Structure
Bispecific Antibodies (BsAb) exhibit poor manufacturability and challenging analytics
S-DUAL™ addresses these issues through its unique structure and properties
- The Problem of BsAbs: Mispairings
-
- Standard BsAb - Desired BsAb
- 8 Possible BsAb Combinations - Probability of correct pairing: 1/8
- Mispairings > Poor peak separation > Process & Analytical issues
-
- Similar physiochemical properties of mispaired BsAb result in difficult peak separation
- Challenging purification, analytics and poor productivity
- S-DUAL™: Address BsAb Mispairings
-
S-DUAL™ BsAb Platform Structure
Asymmetric antibody structure, along with knob-and-holes at the CH3 regions, assures that only your desired BsAb is produced without mispairings.
S-DUAL™ platform expresses BsAb from a single cell line, reducing operational complexity.
Correctly Paired bsAb
Impurities are removed with ease through standard purification methods
- SEC-HPLC: Consistent purities in excess of 98%
- Reducing CE-SDS: Main peak is comprised of the expected ratio of LC/HC, demonstrating correct LC/HC pairing of intact BsAb
SEC-HPLC (%)
- S-DUAL
-
- HMW
- Main
- LMW
- (VEGF x HER2)
-
- 0.6
- 98.5
- 0.9
CE-SDS (%)
- S-DUAL
-
- 1H1L
- 2H1L
- Main
- (VEGF x HER2)
-
- 0.8
- 2.6
- 96.6
CE-SDS - After 3-step purification, Correct hetero-dimerization >96%
*CE-SDS : Capillary Electrophoresis Sodium Dodecyl Sulfate
SEC-HPLC - Transient expression, after 3-step purification, Monomer purity >98%
*SEC-HPLC : Size Exclusion-High-Performance Liquid Chromatography
Low Immunogenicity Risk
S-DUALTM consists of components derived from human immunoglobulin
In silico models support the low immunogenicity of BsAb resulting from the S-DUALTM platform
*In silico assessment of Immunogenicity : Performed by Abeza using their iTope™ and T Cell Epitope Database (TCED™) platform